Abstract
People with HIV-related cognitive impairment may change the way they manage medication regimens, relying on a fixed medication schedule each day to avoid missed doses. Using a medication recall diary, we identified people who took medication on exactly the same schedule over 3 days and those with more variable medication schedules. Patients with low scores on executive and psychomotor tests were more likely to report fixed medication schedules; memory performance, by contrast, was not associated with reported medication regimen. Patients with low scores on executive and psychomotor tests were also less accurate in pouring medicines in the Medication Management Test. More than three fourths of these HIV+ patients assumed that medicines with higher milligram dosages were stronger than medicines with smaller milligram dosages, even across different classes of medicines. In a non-HIV sample, 28% endorsed the belief, suggesting it is a widespread way of thinking about medication strength. A performance test of medication management sheds light on the ways patients take medicines and how beliefs about medicines affect medication regimens.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albert, S. M., Marder, K., Dooneief, G., Bell, K., Sano, M., Todak, G., and Stern, Y. (1995). Neuro-psychological impairment in early HIV infection: A risk factor for work disability. Archives of Neurology, 52, 525–530.
Albert, S. M., Weber, C. M., Todak, G., Polanco, C., Clouse, R., McElhiney, M., Rabkin, J., Stern, Y., and Marder, K. (1999). An observed performance test of medication management ability in HIV: Relation to neuropsychological status and medication adherence outcomes. AIDS and Behavior, 3, 121–128.
Benton, A. L. (1951). The Visual Retention Test. New York: Psychological Corporation.
Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., and Wu, A. W. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12, 255–266.
Concha, M., Selnes, O. A., McArthur, J., Nance-Sproson, T., Updike, M. L., Royal, W., Solomon, L., and Vlahov, D. (1995). Normative data for a brief neuropsychological test battery in a cohort of injecting drug users. International Journal of the Addictions, 30, 832–841.
De Ronchi, D., Faranca, I., Berardi, D., Scudellari, P., Borderi, M., Manfredi, R., and Fratiglioni, L. (2002). Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors. Archives of Neurology, 59, 812–818.
Deutsch, R., Ellis, R. J., McCutchan, J. A., Marcotte, T. D., Letendre, S., Grant, I., and HNRC Group. (2001). AIDS-associated mild cognitive impairment is delayed in the era of highly active antiretroviral therapy. AIDS, 15, 1898–1899.
Dore, G. J., Correll, P. K., Li, Y., Kaldor, J. M., Cooper, D. A., and Brew, B. J. (1999). Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS, 13, 1249–1253.
Ferrando, S., van Gorp, W., McElhiney, M., Goggin, K., Sewell, M., and Rabkin, J. (1998). Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function. AIDS, 12, F65-F70.
Flowers, K. A., and Robertson, C. (1985). The effects of Parkinson's disease on the ability to maintain a mental set. Journal of Neurology, Neurosurgery, and Neuropsychiatry, 48, 517–529.
Horne, R., and Weinman, J. (1999a). Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. Journal of Psychosomatic Research, 47, 555–567.
Horne, R., Weinman, J., and Hankins, M. (1999b). The Beliefs about Medicines Questionnaire: The development and validation of a new method for assessing the cognitive representation of medication. Psychology and Health, 14, 1–24.
Kløve, H. (1963). Clinical neuropsychology. Medical Clinics of North America, 46, 1647–1658.
Marcotte, T. D., Heaton, R. K., Wolfson, T., Taylor, M. J., Alhassoon, O., Arfaa, K., Ellis, R. J., and Grant, I. (1999). The impact of HIV-related neuropsychological dysfunction on driving behavior. The HNRC Group. Journal of the International Neuropsychological Society, 5, 579–592.
Miller, E. N., Satz, P., and Visscher, B. (1991). Computerized and conventional neuropsychological assessment of HIV-1 infected homosexual men. Neurology, 41, 1608–1616.
Nieuwkerk, P. T., Sprangers, M. A., Burger, D. M., Hoetelmans, R. M., Hugen, P. W., Danner, S. A., van Der Ende, M. E., Schneider, M. M., Schrey, G., Meenhorst, P. L., Sprenger, H. G., Kauffmann, R. H., Jambroes, M., Chesney, M. A., de Wolf, F., Lange, J. M., and ATHENA Project. (2001). Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Archives of Internal Medicine, 161, 1962–1968.
Patterson, T. L., Lacro, J., McKibbin, C. L., Moscona, S., Hughs, T., and Jeste, D. V. (2002). Medication management ability assessment: Results from a performance-based measure in older outpatients with schizophrenia. Journal of Clinical Psychopharmacology, 22, 11–19.
Rey, A. (1941). L'examen psychologique dans las cas d'encephalopathie traumatique. (Psychological examination of traumatic encephalopathies.) Archives de Psychologie, 28, 286–340.
Sacktor, N., Lyles, R. H., Skolasky, R., Kleeberger, C., Selnes, O. A., Miller, E. N., Becker, J. T., Cohen, B., and McArthur, J. C. (2001a). HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology, 56, 257–260.
Sacktor, N., Tarwater, P. M., Skolasky, R. L., McArthur, J. C., Selnes, O. A., Becker, J., Cohen, B., and Miller, E. N. (2001b). CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology, 57, 542–544.
Sacktor, N., McDermott, M. P., Marder, K., Schifitto, G., Selnes, O. A., McArthur, J. C., Stern, Y., Albert, S., Palumbo, D., Kieburtz, K., De Marcaida, J. A., Cohen, B., and Epstein, L. (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of Neurovirology, 8, 136–142.
Selnes, O. A., Jacobson, L., Machado, A. M., and MACS Cohort (1993). Normative data for a brief neuropsychological screening battery. Perceptual and Motor Skills, 73, 539–550.
Suarez, S., Baril, L., Stankoff, B., Khellaf, M., Dubois, B., Lubetzki, C., Bricaire, F., and Hauw, J. J. (2001). Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. AIDS, 15, 195–200.
Tozzi, V., Balestra, P., Galgani, S., Galgani, S., Narciso, P., Sampaolesi, A., Antinori, A., Giulianelli, M., Serraino, D., and Ippolito, G. (1999). Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS, 13, 1889–1897.
van Gorp, W. G., Baerwald, J. P., Ferrando, S. J., McElhiney, M. C., and Rabkin, J. G. (1999). The relationship between employment and neuropsychological impairment in HIV infection. Journal of the International Neuropsychological Society, 5, 534–539.
Wechsler, D. (1981). Wechsler Adult Intelligence Scale–Revised. New York: Psychological Corporation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Albert, S.M., Flater, S.R., Clouse, R. et al. Medication Management Skill in HIV: I. Evidence for Adaptation of Medication Management Strategies in People with Cognitive Impairment. II. Evidence for a Pervasive Lay Model of Medication Efficacy. AIDS Behav 7, 329–338 (2003). https://doi.org/10.1023/A:1025404105378
Issue Date:
DOI: https://doi.org/10.1023/A:1025404105378